150 related articles for article (PubMed ID: 38546643)
1. Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Martin-Giacalone BA; Li H; Scheurer ME; Casey DL; Dugan-Perez S; Marquez-Do DA; Muzny D; Gibbs RA; Barkauskas DA; Hall D; Stewart DR; Schiffman JD; McEvoy MT; Khan J; Malkin D; Linardic CM; Crompton BD; Shern JF; Skapek SX; Venkatramani R; Hawkins DS; Sabo A; Plon SE; Lupo PJ
JAMA Netw Open; 2024 Mar; 7(3):e244170. PubMed ID: 38546643
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
[TBL] [Abstract][Full Text] [Related]
3. Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group.
Martin-Giacalone BA; Richard MA; Scheurer ME; Khan J; Sok P; Shetty PB; Chanock SJ; Li SA; Yeager M; Marquez-Do DA; Barkauskas DA; Hall D; McEvoy MT; Brown AL; Sabo A; Scheet P; Huff CD; Skapek SX; Hawkins DS; Venkatramani R; Mirabello L; Lupo PJ
J Natl Cancer Inst; 2023 Jun; 115(6):733-741. PubMed ID: 36951526
[TBL] [Abstract][Full Text] [Related]
4. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
6. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
7. Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Li H; Sisoudiya SD; Martin-Giacalone BA; Khayat MM; Dugan-Perez S; Marquez-Do DA; Scheurer ME; Muzny D; Boerwinkle E; Gibbs RA; Chi YY; Barkauskas DA; Lo T; Hall D; Stewart DR; Schiffman JD; Skapek SX; Hawkins DS; Plon SE; Sabo A; Lupo PJ
J Natl Cancer Inst; 2021 Jul; 113(7):875-883. PubMed ID: 33372952
[TBL] [Abstract][Full Text] [Related]
8. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Harrison DJ; Qumseya A; Xue W; Arnold M; Lautz TB; Hiniker SM; Thomas SM; Venkatramani R; Weiss AR; Mascarenhas L
Pediatr Blood Cancer; 2024 Apr; 71(4):e30847. PubMed ID: 38282125
[TBL] [Abstract][Full Text] [Related]
9. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
[TBL] [Abstract][Full Text] [Related]
10. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
[TBL] [Abstract][Full Text] [Related]
11. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
[TBL] [Abstract][Full Text] [Related]
12. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Stoner JA; Garcia-Henriquez N; Randall RL; Spunt SL; Arndt CA; Kao S; Paidas CN; Million L; Hawkins DS
Cancer; 2011 Jun; 117(11):2541-50. PubMed ID: 24048802
[TBL] [Abstract][Full Text] [Related]
15. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
[TBL] [Abstract][Full Text] [Related]
16. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma.
Kim J; Light N; Subasri V; Young EL; Wegman-Ostrosky T; Barkauskas DA; Hall D; Lupo PJ; Patidar R; Maese LD; Jones K; Wang M; Tavtigian SV; Wu D; Shlien A; Telfer F; Goldenberg A; Skapek SX; Wei JS; Wen X; Catchpoole D; Hawkins DS; Schiffman JD; Khan J; Malkin D; Stewart DR
JCO Precis Oncol; 2021; 5():. PubMed ID: 34095712
[TBL] [Abstract][Full Text] [Related]
18. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Vasquez JC; Luo LY; Hiniker SM; Rhee DS; Dasgupta R; Chen S; Weigel BJ; Xue W; Venkatramani R; Arndt CA
Pediatr Blood Cancer; 2023 Jun; 70(6):e30293. PubMed ID: 36916768
[TBL] [Abstract][Full Text] [Related]
19. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.
Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V
Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612
[TBL] [Abstract][Full Text] [Related]
20. Extremity Rhabdomyosarcoma-An Integrated Clinicopathologic and Genomic Study to Improve Risk Stratification.
de Traux de Wardin H; Xu B; Dermawan JK; Smith MH; Wolden SL; Antonescu CR; Wexler LH
JCO Precis Oncol; 2023 Jun; 7(1):e2200705. PubMed ID: 37315267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
